Benefits
Men's LUTS — Dose-Response Trial Evidence
A pivotal 6-month trial in men over 45 with IPSS ≥8 showed a clear dose-response on lower urinary tract symptoms. The 500 mg/day Flowens™ group dropped IPSS by 4.1 points (p<0.001) and the 250 mg/day group by 3.1 points (p=0.05), versus 1.5 in placebo. The 500 mg group also significantly improved maximum and average urinary flow rate, post-void residual volume, and bladder volume. This is the strongest evidence for any cranberry ingredient on men's LUTS specifically.
Women's OAB — Mixed Trial Results (Honest Framing)
A trial in women with dry overactive bladder compared 500 mg/day cranberry powder vs placebo for 24 weeks. Per-protocol analysis showed reductions in daily micturition, urgency episodes, and improved bladder-condition perception. However, the intent-to-treat analysis showed NO statistically significant difference (p>0.05), and larger trials with longer follow-up are needed. Marketers should be honest about this ITT caveat when making OAB claims.
Approved Health Claims in Canada, Colombia, USA
Flowens™ has obtained regulatory approval for urinary-health product claims in three jurisdictions: Canada (Health Canada), Colombia (INVIMA), and the USA (consistent with the FDA's qualified health claim threshold of 500 mg cranberry fruit powder daily for recurrent UTI risk reduction in healthy women). Multi-jurisdictional recognition makes Flowens™ easier to formulate into compliant products for global markets.
Prostate Inflammation and Quality-of-Life Markers
An earlier 6-month pilot in men with LUTS, elevated PSA, and chronic non-bacterial prostatitis (1,500 mg/day cranberry powder) showed improvements in urinary flow rates, IPSS, quality-of-life scores, and the free-to-total PSA ratio — a marker that improves with reduced prostate inflammation. The later pivotal trial found cranberry's LUTS benefit was independent of BPH and C-reactive protein, suggesting a urothelial rather than primarily anti-inflammatory mechanism.
Whole-Fruit Cranberry Phytochemistry
Flowens™ uses whole-fruit cranberry powder rather than a purified PAC isolate, delivering A-type proanthocyanidins (PACs) plus organic acids (quinic, citric, malic), flavonols (myricetin, quercetin glycosides), anthocyanins, and hydroxycinnamic acids. The full-spectrum approach is the basis of Givaudan's claim that Flowens™ delivers benefits beyond just E. coli anti-adhesion — including the LUTS and OAB symptom outcomes that purified PAC products haven't reproduced.
FDA Qualified Health Claim Threshold Compliance
At 500 mg/day, Flowens™ meets the FDA's 2020 Letter of Enforcement Discretion threshold for cranberry dietary supplements to carry the qualified health claim that they 'may reduce the risk of recurrent UTI' in healthy women with prior UTI history. This is the same 500 mg/day dose used in the pivotal men's LUTS trial and the women's OAB trial — making Flowens™ a single ingredient that can be positioned across UTI prevention, men's urological health, and women's bladder support categories.
Givaudan Sourcing4Good Sustainability
Flowens™ cranberries are sourced through Givaudan's Sourcing4Good initiative — complete traceability from grower to finished ingredient, partnerships with dedicated cranberry farms committed to sustainable practices, and minimized environmental impact. Important for brand positioning in markets where ESG and supply chain transparency claims are increasingly required by retailers and consumers. Differentiates from commodity cranberry extracts with opaque supply chains and frequent adulteration concerns.
Mechanism of action
A-Type PAC Anti-Adhesion of Uropathogenic E. coli
Cranberry's type-A proanthocyanidins (distinguished from the type-B PACs in most other plants) bind to the FimH adhesin on P-fimbriated uropathogenic E. coli — blocking attachment to mannose receptors on bladder epithelial cells. Without anchoring, bacteria cannot colonize and are flushed in urine. This is the dominant mechanism for cranberry's UTI-prevention effect and is shared across all cranberry-derived ingredients including Flowens™.
Urothelial Anti-Inflammatory Action (LUTS Mechanism)
The mechanistic explanation for Flowens™'s LUTS effects in men appears distinct from anti-adhesion — benefits were found independent of CRP levels and BPH status. The leading hypothesis is direct anti-inflammatory action on bladder urothelium plus modest effects on detrusor smooth muscle excitability. Cranberry polyphenols reduce oxidative stress in urothelial cell models and modulate inflammatory cytokine production — both relevant to symptom severity in BPH-associated LUTS and chronic non-bacterial prostatitis.
Whole-Fruit Polyphenol Synergy
Flowens™ delivers the full spectrum of cranberry phytochemistry: A-type PACs, anthocyanins (responsible for the red color and complementary antioxidant activity), flavonols (myricetin, quercetin glycosides), organic acids (quinic acid → hippuric acid for modest urinary acidification), and hydroxycinnamic acids. Givaudan argues this multi-component profile delivers benefits that purified PAC isolates can't match — a hypothesis supported by the LUTS/OAB trial outcomes that haven't been reproduced with high-PAC concentrates alone.
Detrusor Smooth Muscle Modulation (OAB Mechanism)
The proposed mechanism for cranberry's potential OAB benefit involves direct effects on detrusor muscle excitability and afferent signaling from bladder mucosa. Polyphenols may modulate ATP release from urothelium (a key signaling molecule in overactive bladder) and reduce sensory afferent firing. Note: the ITT-negative trial means this mechanistic story remains a hypothesis — the per-protocol numbers are suggestive but not yet confirmed.
Modest Urinary pH Modulation
Cranberry's quinic acid is metabolized to hippuric acid and excreted in urine, producing a modest urinary acidification effect. Historically this was thought to be cranberry's primary antimicrobial mechanism. Modern consensus is that PAC anti-adhesion dominates clinically — the pH change is too small at typical doses to explain the bacterial-inhibition effect. Still, the acidification may contribute modestly to the overall urinary tract health benefit profile.
Clinical trials
6-month double-blind randomized placebo-controlled clinical trial published in World Journal of Urology. Three arms: Flowens™ 500 mg/day, Flowens™ 250 mg/day, or placebo. Primary outcome: IPSS at 3 and 6 months. Secondary outcomes: quality of life, bladder volume, maximum and average urinary flow rates (Qmax, Qave), post-void residual urine volume (PVR), PSA, selenium, IL-6, CRP. Conducted at Palacky University Hospital, Olomouc, Czech Republic.
124 men aged ≥45 with serum PSA <2.5 ng/mL and IPSS ≥8 (n=40 in 500 mg, n=43 in 250 mg, n=41 placebo).
Dose-dependent IPSS reduction: -4.1 in 500 mg group (p<0.001), -3.1 in 250 mg group (p=0.05), -1.5 in placebo. The 500 mg group also showed significant improvements in Qmax, Qave, PVR, and bladder volume vs baseline (p<0.05). 98.4% adherence. No effect on clinical chemistry or hematology markers. Benefit was independent of BPH status and CRP level. The pivotal evidence base for Flowens™ men's LUTS positioning.
24-week double-blind randomized placebo-controlled clinical trial published in Journal of Urology (2020). 500 mg/day dried cranberry powder vs 500 mg placebo. Outcomes measured by 3-day voiding diaries plus Overactive Bladder Questionnaire Short Form, Patient Perception of Bladder Condition (PPBC), Sexual Quality of Life-Female, and Pelvic Floor Distress Inventory. Conducted at Weill Cornell Medicine, New York. Statistical analyses by BIOFORTIS using SAS®.
98 women aged ≥18 with dry overactive bladder randomized (77 completed visits, 60 in per-protocol analysis). Baseline: mean 11.6 daily micturitions, 7.91 urgency episodes, 1.67 nocturia episodes.
Per-protocol analysis: 16.4% reduction in daily micturition, 57.3% reduction in urgency episodes, 39.7% improvement in PPBC. 1.91 fewer daily micturitions and 2.81 fewer daily urgency episodes vs placebo. PPBC score 0.66 points lower than placebo. However, intent-to-treat analysis showed NO statistically significant difference between groups (p>0.05). Authors concluded larger trials with longer follow-up needed before firm OAB conclusions.
6-month randomized controlled clinical trial published in British Journal of Nutrition. 1,500 mg/day dried cranberry powder (3 capsules of 500 mg) vs no cranberry treatment in men with LUTS, elevated PSA, negative prostate biopsy, and histologically confirmed chronic non-bacterial prostatitis (asymptomatic inflammatory prostatitis category IV). Conducted at University Hospital Olomouc, Czech Republic.
42 men aged 45-70 (mean age 63), 21 cranberry / 21 control, all with LUTS + elevated PSA.
Cranberry group showed improvements in maximum urinary flow rate, average flow rate, IPSS, and quality-of-life scores. Free-PSA to total-PSA ratio improved — a marker associated with reduced prostate inflammation. Established the rationale for the larger dose-response Flowens™ pivotal trial that followed. Limitations: smaller sample, open-label control rather than placebo, higher dose than later trial.
Fifth update of the Cochrane evidence synthesis on cranberry products for UTI prevention. Pooled 50 randomized clinical trials including 45 placebo/no-treatment comparisons. Outcomes: symptomatic culture-verified UTIs, side effects, adherence. Stratified by population subgroups.
8,857 participants across 50 trials.
Cranberry products reduced overall UTI risk by 30% (RR 0.70, 95% CI 0.58-0.84). Subgroups: women with recurrent UTIs -26% (RR 0.74), children -54% (RR 0.46), post-bladder-intervention patients -53% (RR 0.47). No benefit in elderly institutionalized, pregnant women, or neuromuscular bladder dysfunction. Cranberry class evidence supporting Flowens™'s base UTI prevention positioning beyond its Flowens-specific LUTS/OAB indications.
2020 FDA review of cranberry clinical evidence in response to an Ocean Spray Qualified Health Claim petition. FDA concluded the evidence was 'limited' but 'credible' for cranberry supplements containing ≥500 mg cranberry fruit powder per day to support a recurrent UTI risk reduction claim in healthy women.
Healthy women with prior UTI history (the population specified in the qualified claim).
FDA issued a letter of enforcement discretion permitting the qualified claim: 'Limited scientific evidence shows that by consuming 500 mg each day of cranberry dietary supplement, healthy women who have had a urinary tract infection may reduce their risk of recurrent UTI.' At 500 mg/day, Flowens™ meets this threshold — the same dose used in its pivotal men's LUTS trial and the women's OAB trial.